GENRX PARACETAMOL IV paracetamol 500 mg/50 mL intravenous infusion for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

genrx paracetamol iv paracetamol 500 mg/50 ml intravenous infusion for injection vial

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: phosphoric acid; alpha lipoic acid; sodium chloride; glycocholic acid; meglumine; water for injections; sodium hydroxide - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the,reduction of fever where an intravenous route of administration is considered clinically necessary.

PARACETAMOL IV APOTEX paracetamol 500 mg/50 mL intravenous infusion for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

paracetamol iv apotex paracetamol 500 mg/50 ml intravenous infusion for injection vial

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: meglumine; phosphoric acid; alpha lipoic acid; glycocholic acid; water for injections; sodium chloride; sodium hydroxide - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the,reduction of fever where an intravenous route of administration is considered clinically necessary.

APO-PARACETAMOL IV paracetamol1 g/100 mL intravenous infusion for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

apo-paracetamol iv paracetamol1 g/100 ml intravenous infusion for injection vial

arrotex pharmaceuticals pty ltd - paracetamol, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: alpha lipoic acid; phosphoric acid; water for injections; sodium hydroxide; sodium chloride; glycocholic acid; meglumine - paracetamol 10 mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the,reduction of fever where an intravenous route of administration is considered clinically necessary.

BAXTER POTASSIUM CHLORIDE 40 mmol and 0.9% SODIUM CHLORIDE 100 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 40 mmol and 0.9% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 29.8 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

BAXTER POTASSIUM CHLORIDE 10 mmol and 0.29% SODIUM CHLORIDE 100 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 10 mmol and 0.29% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - sodium chloride, quantity: 2.92 g/l; potassium chloride, quantity: 7.46 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

ASPEN CIPROFLOXACIN ciprofloxacin injection for intravenous infusion 200mg/100mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

aspen ciprofloxacin ciprofloxacin injection for intravenous infusion 200mg/100ml bag

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

ASPEN CIPROFLOXACIN ciprofloxacin injection for intravenous infusion 100mg/50mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

aspen ciprofloxacin ciprofloxacin injection for intravenous infusion 100mg/50ml bag

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

B Braun 5% Glucose Intravenous Infusion BP 250 mL Bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b braun 5% glucose intravenous infusion bp 250 ml bottle

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established.

B Braun 5% Glucose Intravenous Infusion BP 100 mL Bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b braun 5% glucose intravenous infusion bp 100 ml bottle

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established.

B Braun 0.9% Sodium Chloride Intravenous Infusion BP 250 mL Bottle Australia - English - Department of Health (Therapeutic Goods Administration)

b braun 0.9% sodium chloride intravenous infusion bp 250 ml bottle

b braun australia pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as solvents for intravenously administered drugs where compatibility has been established. may also be used for irrigation of wounds and moistening of wound dressings.